Table 1.

List of clinical trials initiated based on the CTD² Network research findings (two different CTD² centers are based at UCSF)

	CTD2 center	ClinicalTrials.gov identifier	Cancer type	Intervention/treatment
1	Columbia University	NCT04028245	Clear cell renal cell carcinoma	SPARC1 (Spartalizumab and Canakinumab)
2	Columbia University	NCT03211988	Gastroenteropancreatic neuroendocrine tumors	Entinostat (deacetylase inhibitor)
3	Columbia University	NCT02066532	HR−/HER2+ breast cancer	Ruxolitinib (JAK inhibitor) + trastuzumab (HER2 receptor antagonist)
4	Columbia University	NCT02632071	Inflammatory breast cancer	Ricolinostat (HDAC6 inhibitor) + nab-paclitaxel (mitotic inhibitor)
5	Columbia University	NCT03951831	Metastatic prostate cancer	PRIME-CUT (REGN2810 + Degarelix + Leuprolide Acetate + Docetaxel)
6	Columbia University	NCT04301414	Prostate cancer	NEO-RED-P (BMS-986218 and Degarelix + Degarelix)
7	DFCI	NCT03654716	Rhabdoid tumors	ALRN-6924 (MDM2/MDMX inhibitor)
8	Emory University	NCT04348292	Lung non-small cell carcinoma	(Durvalumab + Sirolimus)
9	FHCRC	NCT02508246	Head and neck squamous cell carcinoma	MK-1775 (WEE1 inhibitor) + docetaxel (antimicrotubule agent) + cisplatin (alkylating agent)
10	OHSU	NCT03557970	Acute myeloid leukemia	JNJ-40346527 (inhibitor of CSF1R)
11	OHSU	NCT03874052	Acute myeloid leukemia	Ruxolitinib (JAK inhibitor) + venetoclax (Bcl2 inhibitor)
12	UCSD	NCT03841110	Solid tumors	FT500 (iPSC-derived natural killer cells)
13	UCSF (1)	NCT01402284	Multiple myeloma	Carfilzomib (proteasome inhibitor) + lenalidomide (angiogenesis inhibitor) + dexamethasone (antiinflammatory)
14	UCSF (1)	NCT04085315	Non-small cell lung cancer— EGFR mutant	Osimertinib (EGFR inhibitor) + alisertib (aurora kinase inhibitor)
15	UCSF (2)	NCT02947165	Squamous cell carcinomas	NIS 793 (anti-TGF beta antibody) + PDR 001 (anti-PD-1 antibody)